Skip to main content


We're creating a new version of this page. See preview

  • Letter to the Editor
  • Open Access

Selective killing of circulating tumor cells prevents metastasis and extends survival

Journal of Hematology & Oncology201811:114

  • Received: 1 August 2018
  • Accepted: 27 August 2018
  • Published:

The Correction to this article has been published in Journal of Hematology & Oncology 2019 12:5


Distant metastasis is initiated by circulating tumor cells (CTCs), which are considered to be a determining factor for the degree of metastasis and the survival of cancer patients. Although CTC-based diagnostic approaches are being rapidly developed, limited studies have proven the benefits of CTC elimination, with most studies providing only hypothetical inference because of the technical difficulty in examining the effects of CTC elimination in vivo. We modified photodynamic therapy to specifically eliminate green fluorescent protein (GFP)-expressing CTCs and evaluated the therapeutic efficacy of CTC elimination. When circulating blood is illuminated with a blue laser (λ = 473 nm), the combination of GFP and photosensitizers induces a selective elimination of GFP-expressing CTCs, with limited effect on normal cells. In GFP-expressing cancer cell-infused or transplanted mice models, the treatment suppressed distant metastasis and extended the survival of the tumor-bearing mice. Taken together, CTCs are a core seed to be metastasized into secondary organs and elimination of CTCs may improve the survival of cancer patients.


  • Circulating tumor cells
  • Green fluorescent protein
  • Metastasis
  • Photodynamic therapy
  • Photosensitizers

Circulating tumor cells (CTCs) present in the vascular system are tumor cells that will metastasize from primary or disseminated tumors [1]. Rapid advancements in detection and isolation techniques have led to the remarkable discoveries on the role of CTCs and their association with cancer prognosis [27]. Since an increased number of CTCs are associated with poor prognosis, CTC-targeted therapies may provide a promising new approach which could improve cancer prognosis [8, 9]. However, the unpredictable nature and dynamics of CTCs and the lack of adequate treatment modalities hamper the selective targeting of CTCs.

In the present study, we demonstrate the clinical benefit of selective CTC elimination by using a technique that we developed previously [10]. We used the original photodynamic therapy (PDT) methodology with stepwise modification to selectively kill CTCs using energy transfer between the green fluorescent protein (GFP) expressed by CTCs and the rose bengal (RB) accumulated in the CTCs (Fig. 1a). To mimic the circulation within the blood vessels in vitro, a piece of tubing was connected to a peristaltic pump. GFP+ and GFP NCI-H460 cells were incubated with RB and were passed through the tubing (Fig. 1b). A greater number of propidium iodide-positive cells (which indicates cell death) was observed among the GFP+ NCI-H460 cells than the GFP NCI-H460 cells. Furthermore, GFP cells showed lower damage than GFP+ cells (Fig. 1c). Moreover, the number of dead cells was significantly higher among GFP+ NCI-H460 cells than GFP NCI-H460 cells (Fig. 1d).
Fig. 1
Fig. 1

Concept of selective CTC-targeting PDT and in vitro blood circulation-mimicking system. a Scheme of the selective CTC-targeting PDT. The CTCs derived from a primary tumor circulate in the blood vessels. Since rose bengals (red circles), which are photosensitizers, were injected intravenously prior to CTC-targeting PDT, rose bengals accumulated inside the primary tumor but also the CTCs. When a 473-nm wavelength laser illuminates the blood vessels, the GFP inside the CTCs activates the rose bengal, which produces singlet oxygen. Singlet oxygen induces the destruction of the CTCs inside the blood vessels. b Scheme of the in vitro fluidic system mimicking blood circulation coupled with laser irradiation. c Proportion of dead cells after irradiation with blue laser light. d Differences in cell death between GFP+ (green bar) and GFP (white bar) NCI-H460 cells after up to three rounds of irradiation with the blue laser light. Blue and red signals indicate Hoechst 33342 and propidium iodide (PI) staining, respectively. Y-axis means the ratio of PI-positive cells to total cells. Error bar means standard deviation. *, P < 0.05; **, P < 0.01; ns, non-specific

Then, to test the CTC-targeting PDT in vivo, GFP+ NCI-H460 cells were incubated with RB and injected into mice via the tail vein. Immediately after, a blue laser was illuminated onto the mouse‘s femoral vein, underneath the skin flap (treated group; Fig. 2a). Because the numbers of CTCs were drastically decreased in the intravenous tumor cell injection model (Additional file 1), whole mouse blood was extracted by cardiac puncture about 15 min after tumor cell injection. In the treated group, the number of CTC colonies were significantly decreased in the clonogenic assay (Fig. 2b and Additional file 2a), and GFP expression from the clones was observed (Additional file 2b); hence, each colony had originated from exogenously injected GFP-expressing cancer cells.
Fig. 2
Fig. 2

CTC-targeting PDT in the GFP-expressing cancer cell-injected mice model and in a syngeneic mice model implanted with GFP-expressing cancer cells. a Irradiation of the mouse femoral vein under the skin flap with a 473-nm wavelength laser after GFP-expressing cancer cell injection via the tail vein. b Clonogenic assay using whole blood taken after the experiment. Colonies were stained with Coomassie blue dye, and the number was compared between each group. Error bar means standard deviation. **, P < 0.01. c Irradiation of the mouse femoral vein under the skin flap with a 473-nm wavelength laser in a syngeneic mouse model with implanted GFP-expressing 4T1 cells. d The number of circulating tumor cells in the 2 weeks treatment and untreated mice. Error bar means standard deviation. FOV means the field of view. **, P < 0.01. e Images of the lungs isolated from mice belonging to the 2 weeks treatment and untreated group. f Kaplan–Meier survival curves of the mice in the control and 1 week treatment and 2 weeks treatment groups. p values were calculated using the log-rank test between treatment groups and control. *, P < 0.05; **, P < 0.01

CTC-targeting PDT was also performed in mice with GFP+ metastatic 4T1 cells transplanted into their flanks (Fig. 2c). No changes in primary tumor size (Additional file 3) were observed between treated (irradiated) mice and untreated mice, implying limited effects on GFP normal cells; however, the numbers of CTCs observed in the fluorescent images were significantly decreased in the treated mice compared to those the untreated mice (Fig. 2d and Additional file 4). In the treated group, the number of lung metastatic nodules in the treated mice was significantly lower compared to that in the untreated group (Fig. 2e). Mice receiving treatment for 1 week showed survival gain compared with untreated mice (P = 0.0325) (Fig. 2f). However, the difference was more significant in the mice treated for 2 weeks (P = 0.0026). There was no hematologic difference between the untreated group and the 2 weeks treatment group (Additional file 5). Materials and methods are described in Additional file 6.

To prove the benefits of CTC elimination, we developed an energy transfer-based PDT that targets GFP-expressing CTCs. Using this technique, we attempted to eliminate CTCs and optimize conditions to specifically target CTCs, with minimum damage to normal cells. To our knowledge, this is the first experimental study to demonstrate that the direct killing of CTCs extends survival in vivo. The present study highlights the concept of energy distinction between normal and cancer cells by using a new factor, i.e., cancer cell-specific fluorescence.

Although this is a preliminary study using the externally fluorescence-labeled cancer cells and the injected mouse models, thus, this strategy is not suitable for in vivo targeting therapeutics of CTC; we reveal that clearance of CTC is associated with the reduction of metastasis and extension of survival. In addition, this experiment directly suggests CTCs are a core seed to be metastasized into secondary organs. Advancements in the field of molecular diagnostics have made it possible to use combinations of fluorescence proteins and photosensitizers or molecular-targeted photosensitizers in diverse biological fields, including cancer stem cell-targeted therapy.




Circulating tumor cells


Green fluorescent protein


Photodynamic therapy


Rose bengal



This work was supported by the grants from Kyung Hee University (KHU-20170844 for JW Choi) and the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA17C0039 for YR Kim and CW Jeong).

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Authors’ contributions

YRK and JWC designed the study. YRK and JKY performed in vitro and in vivo experiments. YRK and JWC analyzed the data. JWC created figures for the results. YRK, CWJ, and JWC wrote the manuscript with inputs from all the authors and reviewed the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All animal experiments were approved by the Institutional Animal Care and Use Committee at Kyung Hee University (KHSIRB 18-014) and were performed in compliance with the institutional guidelines.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Hematology/Oncology, Yuseong Sun Hospital, Daejeon, 34084, Republic of Korea
Department of Pharmacology, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea
Department of Life and Nano-pharmaceutical Sciences, Kyung Hee University, Seoul, 02447, Republic of Korea
Department of Urology, Seoul National University Hospital, Seoul, 03080, Republic of Korea


  1. Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16(9):398–406.View ArticleGoogle Scholar
  2. He W, Wang H, Hartmann LC, Cheng J-X, Low PS. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc Natl Acad Sci. 2007;104(28):11760–5.View ArticleGoogle Scholar
  3. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–9.View ArticleGoogle Scholar
  4. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007;253(2):180–204.View ArticleGoogle Scholar
  5. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13(3):920–8.View ArticleGoogle Scholar
  6. Stott SL, Hsu C-H, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci. 2010;107(43):18392–7.View ArticleGoogle Scholar
  7. Zheng S, Lin H, Liu J-Q, Balic M, Datar R, Cote RJ, et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A. 2007;1162(2):154–61.View ArticleGoogle Scholar
  8. Raimondi C, Naso G, Gradilone A, Gianni W, Cortesi E, Gazzaniga P. Circulating tumor cells in cancer therapy: are we off target? Curr Cancer Drug Targets. 2010;10(5):509–18.View ArticleGoogle Scholar
  9. Faltas B. Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells. Front Oncol. 2012;2:68.Google Scholar
  10. Kim YR, Kim JK, Choi JW. Fluorescent cell-selective ablation using an adaptive photodynamic method. Chem Commun. 2017;53(92):12434–7.View ArticleGoogle Scholar


© The Author(s). 2018